News

Ora®, Inc. has been retained by ProQR Therapeutics to provide mobility test services using the Ora-VNC™ for the QR-110 development program for Leber’s Congenital Amaurosis Type 10

News Press Release

Will the Evolving Economic Landscape for Dry Eye Products Impact Investment?

Articles Panel Discussion: George Ousler among industry thought leaders discussing key topics impacting Dry-eye

Keith Lane Discussing Ora’s Standardized Mobility Course (Ora-VNC™)

Articles Presentation: Keith Lane, Senior Director

Presbyopia Therapies Announces Primary Safety and Efficacy Endpoints met in a Phase IIb study of its Topical PRX Ophthalmic Solution for the Treatment of Presbyopia

Articles Press Release

Ora, Inc. Unifies its Clinical Environment with Veeva to Accelerate Trial Execution

News Press Release

TopiVert demonstrates proof of concept in Phase 1/2a study of TOP1630 in the treatment of dry eye syndrome

News Press Release

Veeva Vault CTMS Gains Momentum as Industry Moves to Unify Clinical Applications and Processes

Articles CHICAGO— DIA 2017 Annual Meeting— June 19, 2017

CTMS cloud application streamlines trial management and delivers end-to-end visibility of clinical trials on one platform

Ora presented 16 posters at this year’s ARVO

Articles

Allergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimulating Device Proven to Temporarily Increase Tear Production

Articles DUBLIN, April 25, 2017 /PRNewswire/

AXIM Biotech Retains Ora to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye Indications

Articles NEW YORK, Mar 21, 2017 (GLOBE NEWSWIRE via COMTEX)